An increasing number of studies are describing potential uses of circulating tumour DNA
(ctDNA) in the care of patients with colorectal cancer. Owing to this rapidly developing area …

Testing peripheral blood for circulating tumor DNA (ctDNA) offers a minimally invasive
opportunity to diagnose, characterize, and monitor the disease in individual cancer patients …

Background Numerous studies have shown that cell-free DNA (cfDNA) levels may serve as
a non-invasive biomarker of a broad spectrum of acute and chronic pathologies. However, in …

Liquid biopsies have become of interest as minimally invasive ways to monitor treatment
response in lung cancer patients. Circulating tumor DNA (ctDNA) and protein biomarkers …

With the rapid development of targeted therapies for the treatment of cancer, methods for
predicting response and outcome are in high demand. Non-small cell lung cancer driven by …

Background Liquid biopsy testing, especially molecular tumor profiling of circulating tumor
DNA (ctDNA) in cell-free plasma, has received increasing interest in recent years as it …

High levels of methylated DNA in urine represent an emerging biomarker for non-small cell
lung cancer (NSCLC) detection and are the subject of ongoing research. This study aimed to …

Considerable efforts have been devoted to exploring the breast cancer mutational
landscape to understand its genetic complexity. However, no studies have yet …

The analysis of circulating tumor DNA (ctDNA) released by tumor cells holds great promise
for patients with lymphoma, to refine the diagnostic procedure, clarify the prognosis, monitor …

Reporting on circulating tumor DNA monitoring in metastatic cancer—From clinical validity to
clinical utility - Brenner Thomsen - 2022 - Cancer - Wiley Online Library Skip to Article Content …